Universidad Peruana Cayetano Heredia

Drugs commonly associated with weight change: Umbrella systematic review and meta-analysis (Protocol)

Mostrar el registro sencillo del ítem

dc.contributor.author Domecq, J.P.
dc.contributor.author Prutsky, G.
dc.contributor.author Wang, Z.
dc.contributor.author Elraiyah, T.
dc.contributor.author Brito, J.P.
dc.contributor.author Mauck, K.
dc.contributor.author Lababidi, M.H.
dc.contributor.author Leppin, A.
dc.contributor.author Fidahussein, S.
dc.contributor.author Prokop, L.J.
dc.contributor.author Montori, V.M.
dc.contributor.author Murad, M.H.
dc.date.accessioned 2022-01-18T19:34:36Z
dc.date.available 2022-01-18T19:34:36Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/11050
dc.description.abstract Background: Many drugs and treatments given to patients for various reasons affect their weight. This side effect is of great importance to patients and is also a concern for the treating physician because weight change may lead to the emergence or worsening of other health conditions.Objective: The aim of this study is to summarize the evidence about commonly prescribed drugs and their association with weight change.Methods/Design: Umbrella systematic review and meta-analysis of randomized controlled trials.We will use an umbrella approach to identify eligible randomized controlled trials (RCTs). We will search for systematic reviews of RCTs that compare any of the drugs that have been associated with weight gain (obesogenic) or weight loss (leptogenic); these have been summarized by our experts' panel in a predefined list. Two reviewers will independently determine RCT eligibility. Disagreement will be solved by consensus and arbitrated by a third reviewer. We will extract descriptive, methodological, and efficacy data in duplicate. Our primary continuous outcomes will be weight loss or gain expressed as a mean difference (MD) for weight (kg) or BMI (kg/m2). We will calculate the MD considering the mean difference in weight or BMI between baseline and the last available follow-up in both study arms (drugs and placebo). Our primary dichotomous outcome, presented as a relative risk, will compare the ratio of the incidence of weight change in each trial arm. When possible, results will be pooled using classic random-effects meta-analyses and a summary estimate with 95% confidence interval will provided. We will use the I2 statistic and Cochran's Q test to assess heterogeneity. The risk of bias will be assessed using the Cochrane risk of bias tool. Publication bias, if appropriate, will be evaluated, as well as overall strength of the evidence.Discussion: This systematic review will offer the opportunity to generate a ranking of commonly prescribed drugs in terms of their effect on weight, allowing guideline developers and patient-physician dyad to choose between available therapies. en_US
dc.language.iso eng
dc.publisher BioMed Central
dc.relation.ispartofseries Systematic Reviews
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject lithium en_US
dc.subject side effect en_US
dc.subject unindexed drug en_US
dc.subject methodology en_US
dc.subject follow up en_US
dc.subject body mass en_US
dc.subject Body Mass Index en_US
dc.subject Body Weight en_US
dc.subject drug effect en_US
dc.subject Randomized Controlled Trials as Topic en_US
dc.subject Research Design en_US
dc.subject systematic review en_US
dc.subject weight reduction en_US
dc.subject Weight Gain en_US
dc.subject exendin 4 en_US
dc.subject carbamazepine en_US
dc.subject cabergoline en_US
dc.subject growth hormone en_US
dc.subject Weight Loss en_US
dc.subject meta analysis (topic) en_US
dc.subject metformin en_US
dc.subject fluoxetine en_US
dc.subject lamotrigine en_US
dc.subject Review Literature as Topic en_US
dc.subject Systematic review en_US
dc.subject Adults en_US
dc.subject Meta-Analysis as Topic en_US
dc.subject literature en_US
dc.subject 4 hydroxybutyric acid en_US
dc.subject acarbose en_US
dc.subject amfebutamone en_US
dc.subject amitriptyline en_US
dc.subject aripiprazole en_US
dc.subject atenolol en_US
dc.subject bromocriptine en_US
dc.subject citalopram en_US
dc.subject clozapine en_US
dc.subject doxazosin mesylate en_US
dc.subject doxepin en_US
dc.subject Drug en_US
dc.subject duloxetine en_US
dc.subject escitalopram en_US
dc.subject fluvoxamine en_US
dc.subject gabapentin en_US
dc.subject Leptogenic en_US
dc.subject leuprorelin en_US
dc.subject liraglutide en_US
dc.subject metoprolol en_US
dc.subject miglitol en_US
dc.subject nefazodone en_US
dc.subject Obesogenic en_US
dc.subject octreotide en_US
dc.subject Weight change en_US
dc.title Drugs commonly associated with weight change: Umbrella systematic review and meta-analysis (Protocol) en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1186/2046-4053-1-44
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.00
dc.relation.issn 2046-4053


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas